EGFR and non-small cell lung carcinoma: The FDA has approved two EGFR-specifc TKIs, Iressa (Gefitinib) [December 2004] and Tarceva (Erlotinib) [November 2004], for the treatment of non-small cell lung carcinoma (Morgillo et al. 2007).